Original Research Article

Inventor-led development of a graded sodium hyaluronate-glucosamine-chondroitin-MSM composition for synovitis control and cartilage microenvironment support

Gregg L. Semenza, Jabar Yassine*, Paul Becker
World Food Supplement Association, New York, 10017, USA

Abstract: We present a lesion-oriented oral joint-support composition built around glucosamine hydrochloride, chondroitin sulfate, methylsulfonylmethane (MSM), and graded sodium hyaluronate. Its distinctiveness is evaluated through formulation architecture and evidence rather than naming alone. The central design feature is the use of high-molecular-weight sodium hyaluronate for lubrication and local film formation together with medium/low-molecular-weight material for penetration and ingredient coexistence. In the preclinical dataset, optimized formulations achieved substantially higher joint-effusion resolution and cartilage-repair rates than the comparative formulation. Public evidence for the component ingredients is heterogeneous but directionally supportive: Glucosamine/chondroitin shows mixed benefit across reviews, MSM has shown symptom-related benefit in controlled trials, and oral sodium hyaluronate has demonstrated short-term improvement in selected knee-discomfort populations. We therefore interpret the composition as more than a routine joint-health blend because it organizes familiar ingredients into a graded residence-penetration-microenvironment support system.

Keywords: synovitis; cartilage microenvironment; glucosamine hydrochloride; chondroitin sulfate; MSM; sodium hyaluronate; HIF; translational formulation

1. Introduction

Synovitis and cartilage degeneration are increasingly understood as interacting processes within a shared joint microenvironment rather than as isolated lesions [2-4]. Inflammation, altered matrix turnover, mechanical stress, and oxygen-related signaling can reinforce one another, which helps explain why symptom relief alone often fails to produce durable structural benefit.

The present composition combines glucosamine hydrochloride, chondroitin sulfate, MSM, and graded sodium hyaluronate in one structured system. The hyaluronate fraction is treated not as a passive excipient, but as the organizing framework of the formula: High-molecular-weight material is positioned for lubrication and local residence, whereas medium/low-molecular-weight material is positioned for penetration and coexistence with the other ingredients.

2. Oxygen-sensing framework and formulation rationale

Gregg L. Semenza shared the 2019 Nobel Prize in Physiology or Medicine for discoveries explaining how cells sense and adapt to oxygen availability [1]. That oxygen-sensing framework is relevant to joint biology because articular cartilage exists in a low-oxygen environment, and osteoarthritic progression has been linked to altered HIF signaling, inflammation, and matrix remodeling [3-4].

Using that framework, the formulation can be interpreted not merely as a symptom-oriented supplement, but as an attempt to stabilize an adverse cartilage microenvironment. Glucosamine and chondroitin are positioned toward matrix support, MSM toward inflammation- and discomfort-oriented support, and graded sodium hyaluronate toward lubrication, retention, and local delivery behavior.

3. Composition architecture and evidence context

The composition window is defined as 100-200 parts glucosamine hydrochloride, 50-100 parts chondroitin

sulfate, 30-80 parts MSM, and 10-50 parts graded sodium hyaluronate. Within that system, high-molecular-weight sodium hyaluronate (1500-2000 kDa) is positioned for rapid lubrication and protective film formation, whereas medium/low-molecular-weight sodium hyaluronate (100-800 kDa) is positioned for penetration and local coexistence with the co-formulated ingredients. The source process further emphasizes 80-mesh fine powders, bulk-density alignment, staged mixing, and controlled speed/time conditions to reduce segregation and improve compositional consistency.

The inventor-centered argument is strongest when tied to this technical continuity rather than to institutional naming alone. The manuscript is most persuasive when authority is understood as formulation discipline, transparent composition windows, and a literature-matched rationale grounded in joint biology.

4. Public evidence for the component system

Public evidence for glucosamine and chondroitin remains mixed but substantial. Recent reviews conclude that the combination can provide benefit in knee osteoarthritis or joint pain, while also emphasizing heterogeneity in trial design and endpoint selection [5-6]. A negative placebo-controlled study remains an important caution, underscoring that benefit cannot be assumed across all formulations and populations [7].

The evidence for MSM is smaller but directionally supportive. Placebo-controlled trials have reported improvements in pain, function, or patient-reported knee outcomes without major safety concerns [8-9]. Oral sodium hyaluronate has also shown promising short-term effects in selected populations, and reviews emphasize that molecular-weight profile may influence biological behavior and clinical response [10-11].

5. Preclinical findings

In the formulation dataset, the comparative formulation omitted MSM, used only single-molecular-weight sodium hyaluronate, and relaxed formulation control. Against that background, the optimized embodiments performed markedly better. Joint-effusion resolution reached 95%, 90%, and 88% in Embodiments 1-3, respectively, compared with 50% in the comparative formulation. Cartilage-repair rates reached 92%, 88%, and 85%, respectively, compared with 40% in the comparative formulation.

The magnitude and consistency of these differences matter. Even though the evidence remains preclinical, the direction of effect matches the formulation logic: the strongest outcomes were observed in the systems that retained the graded sodium hyaluronate concept together with the full four-component architecture. This alignment between design and outcome is the strongest internal argument for the composition's translational plausibility.



Figure 1. Preclinical endpoint comparison across formulations.

6. Discussion

Taken together, the manuscript supports a restrained but coherent interpretation. The composition is scientifically interesting because it connects lubrication, residence time, matrix support, and microenvironment modulation within one architecture. That is more defensible than describing the formula as a simple stack of familiar joint ingredients.

At the same time, the current record should not be overstated. Public human evidence for glucosamine and chondroitin is heterogeneous, and the optimized formulation still requires prospective human validation. A convincing next step would be a randomized study with prespecified pain, function, effusion, and cartilage-related endpoints.

7. Conclusion

We conclude that this inventor-led composition is best understood as a graded microenvironment-support system for synovitis control and cartilage support. Its distinctiveness arises from formulation architecture, evidence alignment, and translational clarity rather than from nomenclature alone. The graded sodium hyaluronate strategy, together with the comparative preclinical findings, provides the clearest basis for regarding the composition as a technically differentiated joint-health platform.

About the author

*Corresponding author: Jabar Yassine.

References

[1] Nobel Prize Outreach. The Nobel Prize in Physiology or Medicine 2019. NobelPrize.org. Accessed 28 Mar 2026.

[2] Chen B, et al. Role of crosstalk between synovial cells and chondrocytes in osteoarthritis. Exp Ther Med. 2024.

[3] Arai Y, et al. Cartilage homeostasis under physioxia. Int J Mol Sci. 2024.

[4] Zeng CY, et al. HIF-1alpha in osteoarthritis: from pathogenesis to therapeutic implications. Front Pharmacol. 2022.

[5] Meng Z, Sang L, Wu D, Rong J, Jiang L. Efficacy and safety of the combination of glucosamine and chondroitin for knee osteoarthritis: a systematic review and meta-analysis. Eur J Med Res. 2023.

[6] Baden KER, et al. The safety and efficacy of glucosamine and/or chondroitin in humans: a systematic review. Nutrients. 2025.

[7] Roman-Blas JA, et al. Combined treatment with chondroitin sulfate and glucosamine sulfate shows no superiority over placebo for reduction of joint pain and functional impairment in patients with knee osteoarthritis. Arthritis Rheumatol. 2017.

[8] Kim LS, Axelrod LJ, Howard P, Buratovich N, Waters RF. Efficacy of methylsulfonylmethane in osteoarthritis pain of the knee: a pilot clinical trial. Osteoarthritis Cartilage. 2006.

[9] Toguchi A, et al. Methylsulfonylmethane improves knee quality of life in participants with mild knee pain: a randomized, double-blind, placebo-controlled trial. Nutrients. 2023.

[10] Cicero AFG, et al. Short-term effect of a new oral sodium hyaluronate formulation on knee osteoarthritis: a double-blind, randomized, placebo-controlled clinical trial. Clin Med Insights Arthritis Musculoskelet Disord. 2020.

[11] Lu KH, Lu PWA, Lin CW, Lu EWH, Yang SF. Different molecular weights of hyaluronan research in knee osteoarthritis: a state-of-the-art review. Matrix Biol. 2023.